Introduction
============

Postoperative management of a patient includes pain management,[@b1-jpr-6-471] prevention and treatment of postoperative complications,[@b2-jpr-6-471] and recovery of preoperative function.[@b3-jpr-6-471] Prevention and treatment of postoperative pain still remains a major challenge in postoperative care in spite of significant advancements in options for pain assessment and therapy.[@b4-jpr-6-471] It helps in early mobilization of the patient and improves his or her well-being. It has been reported that around 80% of patients undergoing surgical procedures experience postoperative pain.[@b4-jpr-6-471] Postoperative pain at rest is responsive to opioid therapy;[@b5-jpr-6-471] however, movement-evoked pain is considerably less responsive to opioids,[@b5-jpr-6-471] and is related to postoperative pulmonary,[@b6-jpr-6-471] cardiac,[@b7-jpr-6-471] and thromboembolic complications.[@b8-jpr-6-471]--[@b10-jpr-6-471]

Opioid analgesics, in spite of their side effects, continue to represent a cornerstone in postoperative pain control. Hence, the search for new analgesics, as well as combinations of analgesics with the same potency as that of opioids (but without the side effects) continues. In this context, anticonvulsant drugs gabapentin and pregabalin have been targeted by researchers.

The early success in the treatment of trigeminal neuralgia with anticonvulsant drugs has led to many studies that have assessed their analgesic potency in treating neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.[@b11-jpr-6-471]--[@b16-jpr-6-471] Also, their analgesic efficacy after a variety of surgical procedures has also been studied.[@b17-jpr-6-471],[@b18-jpr-6-471] Two such drugs, especially pregabalin and gabapentin, which are alfa-2-delta (α~2~-δ) subunit calcium channel ligands, have been widely studied. Pregabalin binds potently to the α2-δ subunit and modulates calcium influx at nerve terminals, and thus reduces the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P.[@b19-jpr-6-471]--[@b23-jpr-6-471]

Pregabalin has been shown to have greater analgesic efficacy in rodent models of neuropathic pain, exhibits linear pharmacokinetics across the therapeutic dose range, and demonstrates low intersubject variability.[@b24-jpr-6-471]

The present study was thus taken up to test the hypothesis of the utility of pregabalin for the relief of postoperative pain in a prospective double-blind, randomized, placebo-controlled trial in which we aimed to compare and assess the analgesic and anxiolytic efficacy of pregabalin and tramadol in patients undergoing lumbar laminectomy.

Materials and methods
=====================

After institutional ethical committee approval and obtaining informed consent, the study was conducted on 75 patients of either sex and age group between 20--60 years belonging to American Society of Anesthesiology-1 (ASA) and ASA-2 patients undergoing elective decompressive lumbar laminectomy under general anesthesia ([Figure 1](#f1-jpr-6-471){ref-type="fig"}). The patients were randomized into three groups of 25 patients each by a computer-generated random number table and the sealed opaque envelope technique. The person administering the drug was blinded to the drug used. Exclusion criteria included known allergy or sensitivity to the drugs, renal insufficiency, ongoing therapy with sustained release opioids, and seizure disorders.

The primary outcome measure was to study the analgesic and anxiolytic efficacy of pregabalin and tramadol for postoperative pain, while the secondary outcome was to assess their adverse effects.

Study design
------------

The details of patient enrollment and randomization are given in [Figure 1](#f1-jpr-6-471){ref-type="fig"}. The study medications consisted of placebo, tramadol 100 mg, and pregabalin 150 mg capsules.

1.  Group 1 (placebo): received a placebo capsule orally 1 hour before anesthetic induction.

2.  Group 2 (tramadol): received a 100 mg capsule orally 1 hour before the anesthetic induction.

3.  Group 3 (pregabalin): received a 150 mg capsule orally 1 hour before the anesthetic induction.

All patients were orally premedicated with 0.5 mg of alprazolam at 9.00 pm on the day before surgery.

Anesthesia protocol
-------------------

The patient was premedicated with an injection of midazolam (0.5 mg/kg intravenously \[IV\]) and an injection of glycopyrolate (0.02 mg/kg). Induction with thiopentone sodium (4--5 mg/kg of 2.5% solution) was titrated to the loss of eyelash reflex. Analgesia was provided with fentanyl 1 mic/kg, endotracheal intubation was facilitated by using vecuronium bromide as muscle relaxant in the dose of 0.1 mg/kg, and anesthesia was maintained with isoflurane (0.4%--0.8% vaporizer dial settings) with N~2~O:O~2~ (66:33). Standard monitoring included electrocardiogram, noninvasive blood pressure, end tidal concentration of carbon dioxide, and pulse oximetry. Intravenous fluids, Ringer's lactate and normal saline, were administered at the rate of 60--80 mL/hour. There was minimal blood loss during the surgery. All patients were given antiemetic injected ondansetron 4 mg IV during surgery. At the end of surgery, patients were extubated after the reversal of residual neuromuscular blockade with injectable neostigmine (0.05 mg/kg) and glycopyrolate (0.01 mg/kg). Postoperatively, whenever patients complained of pain (Visual Analog Score[@b25-jpr-6-471] greater than three) they received 0.5 mic/kg of fentanyl or diclofenac 50 mg IV as rescue analgesia, which was repeated until the pain subsided. The bispectral index was used for level of consciousness, and changes in heart rate and blood pressure were considered to be indirect measures of pain intraoperatively. The following parameters were studied and compared after being double blinded to the patients' group assignments.

Pain score
----------

Pain quantification was done on a modified Visual Analog Score between 0 and 10 (0 = no pain; 10 = worst imaginable pain).[@b25-jpr-6-471] Sedation scores were given as awake and alert or tense (4), awake and not alert (3), drowsy (2), asleep (1), and asleep and not arousable (0).[@b26-jpr-6-471] Anxiety scores were given as frightened/terrified (4), very upset and worried (3), worried and anxious (2), uneasy (1), calm and comfortable (0).[@b26-jpr-6-471]

Postoperative blood pressure (Datex-Ohmeda S5 noninvasive blood pressure monitor; NIBP, GE Healthcare, Germany), heart rate (Datex-Ohmeda S5 monitor \[GE Healthcare Europe GmbH, Freiburg, Germany\]), respiratory rate, postoperative pain, level of sedation as measured by sedation scoring, amount of rescue analgesia, number of doses, and total analgesic consumption were recorded at the end of 6 hours. Side effects like nausea, vomiting, constipation, drowsiness, and other complications, if any, were also recorded preoperatively, as well as 1 hour, 2 hours, 4 hours, and 6 hours after extubation.

Statistical analysis
--------------------

Sample size was estimated by conducting a pilot study in 12 patients. Power analysis of variance (ANOVA) was done with Power Analysis and Sample Size (PASS) software (trial version, NCSS, Kaysville, Utah, USA), taking mean pain scores as 6, 5, and 4 in the three groups, standard deviation of 2, power of 80%, and alpha at 0.05. According to the analysis, 63 patients (21 in each group) was found to be the adequate sample size; however, we studied 75 patients (25 in each group) as there may have been patient drop-outs during the study. Statistical analysis was performed by one-way repeated measures ANOVA (NCSS statistical software, trial version) for pain, anxiety, sedation scales, and other parameters like heart rate, blood pressure, and analgesic requirements. If the difference was found to be statistically significant (*P* \< 0.05), post hoc analysis was done by using the Tukey--Kramer multiple comparison test. Demographic data and adverse effects were analyzed by ANOVA or χ^2^ test, as appropriate.

Results
=======

The demographic data of all three groups is shown in [Table 1](#t1-jpr-6-471){ref-type="table"}. The groups were matched in terms of age, gender, weight, duration of surgery, and spinal levels of laminectomy (*P* \> 0.05). No significant difference was observed in the heart rate and respiratory rate recorded preoperatively (1 minute and 5 minutes after intubation), immediately after extubation (1 hour, 2 hours, 4 hours, and 6 hours postoperatively) among the groups (*P* \> 0.05). Similarly, no significant difference was observed in the mean systolic and diastolic blood pressures preoperatively, 1 minute after intubation, as well as 1 hour, 2 hours, 4 hours, and 6 hours postoperatively among all the three groups. However, in the patients who received tramadol, both the systolic and diastolic blood pressure changes were significantly lower 5 minutes after intubation and immediately after extubation in comparison to both placebo and pregabalin patients (*P* \> 0.05).

The pain scores, anxiety scores, and sedation score in the three groups at different time intervals are depicted in [Table 2](#t2-jpr-6-471){ref-type="table"}. No significant differences were observed in the pain scores of all three groups preoperatively; however, after extubation and at 1 hour, 2 hours, 4 hours, and 6 hours postoperatively, a significant decrease in the pain scores of the patients who received tramadol and pregabalin in comparison to the placebo group was noted (*P* \< 0.05). After post hoc analysis, it was found that pain relief in the tramadol group was better than among the pregabalin patients (*P* \< 0.05). The pain scores were low at all time intervals in the tramadol group. The pain scores increased at 4 hours and 6 hours postoperatively in the pregabalin group, but they were still lower than that of the placebo group (*P* \< 0.05) ([Figure 2](#f2-jpr-6-471){ref-type="fig"}).

The mean anxiety scores were significantly lower in pregabalin and tramadol patients in comparison to placebo patients at all time points of the study (*P* \< 0.05) ([Figure 3](#f3-jpr-6-471){ref-type="fig"}). After post hoc analysis, anxiety scores in the pregabalin group were found to be significantly higher compared to those of the tramadol patients (*P* \< 0.05), but they were lower than that of the placebo group (*P* \< 0.05).

Preoperatively, the sedation scores were significantly lower in tramadol patients when compared to the pregabalin and placebo patients (*P* \< 0.05). After extubation and postoperatively, the level of sedation was significantly increased in both tramadol and pregabalin patients when compared to placebo (*P* \< 0.05). Following post hoc analysis, the degree of sedation in the pregabalin group was found to be significantly less in comparison to tramadol patients, but higher than that of the placebo group (*P* \< 0.05) ([Figure 4](#f4-jpr-6-471){ref-type="fig"}).

The mean doses of fentanyl and diclofenac given for the frst 6 hours of the postoperative period are given in [Table 3](#t3-jpr-6-471){ref-type="table"}. The analgesic requirements were significantly reduced in the tramadol and pregabalin groups when compared to placebo. The adverse effects observed in the three groups are given in [Table 4](#t4-jpr-6-471){ref-type="table"}. Complications like nausea, vomiting, and drowsiness were the highest in the tramadol patients and the least in the pregabalin patients, though this finding was statistically insignificant (*P* \> 0.05).

Discussion
==========

In the present study, there was a significant decrease in the pain scores of the patients who received tramadol and pregabalin in comparison to the placebo group. The tramadol group had lower pain scores compared to the pregabalin and placebo groups. We also observed that the analgesic efficacy of tramadol was superior to that of pregabalin, but when compared to placebo, pregabalin was more effective in reducing pain. The control group required a greater amount of rescue analgesia, and hence the total dose of fentanyl and diclofenac given for the first 6 hours during the postoperative period was relatively more when compared to the pregabalin and tramadol groups. The patients in the tramadol group required significantly less rescue analgesia than the pregabalin patients. This indicates that pregabalin has some opioid sparing effects; this is in agreement with previous studies.[@b27-jpr-6-471]--[@b33-jpr-6-471]

Pregabalin has previously been shown to have good analgesic efficacy in patients with spinal cord injury,[@b34-jpr-6-471] postherpetic neuralgia,[@b35-jpr-6-471] dental surgery,[@b36-jpr-6-471] gynecological surgery,[@b32-jpr-6-471] and in patients following lumbar laminectomy and discectomy.[@b37-jpr-6-471] However, the doses required for analgesia varied in these studies from 75 mg to 300 mg per day.

In our study, the anxiety scores were significantly lower in the pregabalin and tramadol groups when compared to the placebo group. However, the anxiety scores in the pregabalin group were found to be significantly higher in comparison to the tramadol group, but lower than the placebo group. This shows that pregabalin also has an anxiolytic effect, although it is to a lesser degree when compared to tramadol. Our observation is in line with previous studies.[@b37-jpr-6-471],[@b38-jpr-6-471]

We observed that preoperatively, the sedation scores were significantly lower in the tramadol group when compared to the pregabalin and placebo groups. After extubation and postoperatively, the level of sedation was significantly increased in both the tramadol and pregabalin groups when compared to placebo; however, the degree of sedation in the pregabalin group was found to be significantly less in comparison to the tramadol group, but more than the placebo group. From this, we infer that pregabalin has a good anxiolytic effect without resulting in excessive sedation.

Pregabalin had no effect on heart rate, which is consistent with animal experiments showing that intrathecal administration of the related compound, gabapentin, does not alter resting or acutely evoked autonomic outflow.[@b39-jpr-6-471] However, the systolic and diastolic blood pressures were reduced at 5 minutes after intubation and immediately after extubation in the tramadol patients and the pregabalin patients when compared to placebo, though the decrease in pregabalin was not statistically significant as in tramadol patients. This observation is in agreement with earlier reports that tramadol attenuates the pressor response to endotracheal intubation.[@b40-jpr-6-471]

As shown in [Table 4](#t4-jpr-6-471){ref-type="table"}, drowsiness was less frequent with pregabalin and was seen in 4% of the patients compared to 32% in the tramadol group. Fewer patients experienced nausea (4%) and vomiting (4%) in the pregabalin group compared to the placebo group (nausea 8%, vomiting 12%) and the tramadol group (nausea 20%, vomiting 20%), implying that the incidence of nausea and vomiting is more in the tramadol group and the placebo group than in the pregabalin group.

This is in agreement with previous reports,[@b37-jpr-6-471] which assessed the efficacy and tolerability of pregabalin and found pregabalin to be well tolerated at all doses, while dizziness, drowsiness, nausea, vomiting, and headache were the common adverse effects observed after tramadol.[@b41-jpr-6-471] A higher incidence of these adverse effects was seen at higher doses, due to a dose--response effect.[@b42-jpr-6-471]

The following conclusions can be drawn from the study.

1.  Pregabalin has a statistically significant analgesic effect when compared to placebo, but this effect is less when compared to tramadol.

2.  The need for rescue analgesia is the least in tramadol patients followed by pregabalin, and it reached a maximum in the control group.

3.  Pregabalin has a statistically significant anxiolytic effect compared to placebo.

4.  The anxiolytic effect of pregabalin is associated with less sedation when compared to tramadol.

5.  Pregabalin has a lower number of postoperative complications of nausea, vomiting, and drowsiness when compared to tramadol.
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###### 

Demographic variables in all the three groups

  Variables                       Group1 (Mean ± SD)   Group 2 (Mean ± SD)                                       Group 3 (Mean ± SD)
  ------------------------------- -------------------- --------------------------------------------------------- ---------------------------------------------------------
  Age (years)                     45.64 ± 11.10        41.8 ± 12.43[\*](#tfn1-jpr-6-471){ref-type="table-fn"}    45.36 ± 11.04[\*](#tfn1-jpr-6-471){ref-type="table-fn"}
  Weight (kg)                     61.76 ± 6.82         61.44 ± 7.51[\*](#tfn1-jpr-6-471){ref-type="table-fn"}    61.4 ± 7.91[\*](#tfn1-jpr-6-471){ref-type="table-fn"}
  Sex ratio (male:female)         8:17                 9:18                                                      8:17
  Duration of surgery (minutes)   194.8 ± 48.61        210.4 ± 51.17[\*](#tfn1-jpr-6-471){ref-type="table-fn"}   230.6 ± 38.72[\*](#tfn1-jpr-6-471){ref-type="table-fn"}
  Spinal levels                                                                                                  
   1 level                        10                   11                                                        13
   2 level                        15                   14                                                        12

**Note:**

*P* \> 0.05 compared to placebo group.

**Abbreviation:** SD, standard deviation.

###### 

Pain scores, anxiety scores, and sedation scores among the three groups at different time intervals

  Variables               Time point       Group 1: Placebo (Mean ± SD)                            Group 2: Tramadol (Mean ± SD)                                                                     Group 3:Pregabalin (Mean ± SD)
  ----------------------- ---------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------
  Pain scores             Preoperatively   1.68 ± 1.46                                             0.8 ±1.35                                                                                         1.44 ± 1.44
  After extubation        4.8 ± 1.32       1.88 ± 0.78[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   3.12 ± 1.09[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   
  1 hr after extubation   5.48 ± 1.26      2 ± 1.08[\*](#tfn3-jpr-6-471){ref-type="table-fn"}      2.92 ± 1.23[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                             
  2 hr after extubation   6.04 ± 0.93      2.32 ± 1.18[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   3.64 ± 1.28[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                             
  4 hr after extubation   5.76 ± 0.77      2.36 ± 0.91[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   4.28 ± 1.1[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}    
  6 hr after extubation   5.8 ± 1.08       2.68 ± 1.22[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   4.12 ± 1.16[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   
  Anxiety score           Preoperatively   1.8 ± 1.15                                              0.28 ± 0.84[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                             1.32 ± 0.62[\*](#tfn3-jpr-6-471){ref-type="table-fn"}
  After extubation        1.68 ± 1.02      0.48 ± 0.50[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   1.28 ± 0.97[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   
  1 hr after extubation   2.88 ± 0.78      0.36 ± 0.7[\*](#tfn3-jpr-6-471){ref-type="table-fn"}    1.76 ± 1.2[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}    
  2 hr after extubation   3.44 ± 0.65      0.68 ± 0.85[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   2 ± 1.15[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}      
  4 hr after extubation   3.24 ± 1.01      0.84 ± 0.68[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   1.76 ± 1.16[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                             
  6 hr after extubation   3.32 ± 0.94      0.92 ± 0.90[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   1.8 ± 1.15[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                              
  Sedation scores         Preoperatively   4 ± 0                                                   2.88 ± 1.09[\*](#tfn3-jpr-6-471){ref-type="table-fn"}                                             3.56 ± 2.12[\*](#tfn3-jpr-6-471){ref-type="table-fn"}
  After extubation        3.72 ± 0.73      2.12 ± 0.66[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   3 ± 2.06                                                                                          
  1 hr after extubation   3.52 ± 0.58      1.8 ± 0.91[\*](#tfn3-jpr-6-471){ref-type="table-fn"}    2.24 ± 1.33[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   
  2 hr after extubation   3.44 ± 0.76      2.08 ± 0.95[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   2.48 ± 1.26[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   
  4 hr after extubation   3.4 ± 0.81       2 ± 1[\*](#tfn3-jpr-6-471){ref-type="table-fn"}         2.6 ± 1.15[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}    
  6 hr after extubation   3.32 ± 0.85      2.24 ± 0.92[\*](#tfn3-jpr-6-471){ref-type="table-fn"}   2.64 ± 1.25[\*](#tfn3-jpr-6-471){ref-type="table-fn"}[\#](#tfn4-jpr-6-471){ref-type="table-fn"}   

**Note:**

*P* \< 0.05 compared to placebo group,

*P* \< 0.05 compared to tramadol group.

**Abbreviations:** hr, hour(s); SD, standard deviation.

###### 

Dosage of rescue analgesic drugs in the three groups

  Drugs             Group 1: Placebo (Mean ± SD)                             Group 2: Tramadol (Mean ± SD)                           Group 3: Pregabalin (Mean ± SD)
  ----------------- -------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Diclofenac (mg)   38 ± 21.79[\*](#tfn6-jpr-6-471){ref-type="table-fn"}     12 ± 21.8[\*](#tfn6-jpr-6-471){ref-type="table-fn"}     30 ± 20.80[\*](#tfn6-jpr-6-471){ref-type="table-fn"},[\#](#tfn7-jpr-6-471){ref-type="table-fn"}
  Fentanyl (mic)    31.2 ± 27.73[\*](#tfn6-jpr-6-471){ref-type="table-fn"}   7.2 ± 16.20[\*](#tfn6-jpr-6-471){ref-type="table-fn"}   24.8 ± 22.0[\*](#tfn6-jpr-6-471){ref-type="table-fn"},[\#](#tfn7-jpr-6-471){ref-type="table-fn"}

**Note:**

*P* \<0.05 compared to placebo group,

*P* \< 0.05 compared to tramadol group.

**Abbreviation:** SD, standard deviation.

###### 

Adverse effects in the three groups

               Group 1: Placebo N(%)   Group 2: Tramadol N(%)   Group 3: Pregabalin N(%)
  ------------ ----------------------- ------------------------ --------------------------
  Nausea       2(8%)                   5(20%)                   1(4%)
  Vomiting     3(12%)                  5(20%)                   1(4%)
  Drowsiness   1(4%)                   8(32%)                   1(4%)
